# US 8,772,323 B2 · Benzoxazole- and tetrahydrobenzoxazole-substituted pyridazinones as GPR119 agonists

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,772,323 B2
- Document ID: US8772323B2
- Status: Granted
- Kind: B2
- Application number: 13/696,094
- Filed: 2011-05-06
- Published: 2013-07-04
- Granted: 2014-07-08
- Earliest claimed: 2010-05-07
- Assignees: Boehringer Ingelheim International GmbH
- Applicants: Matthias Grauert; Remko Bakker; Steffen Breitfelder; Frank Buettner; Peter Eickelmann; Thomas Fox; Marc Grundl; Thorsten Lehmann-Lintz; Wolfgang Rist
- Inventors: Matthias Grauert; Remko Bakker; Steffen Breitfelder; Frank Buettner; Peter Eickelmann; Thomas Fox; Marc Grundl; Thorsten Lehmann-Lintz; Wolfgang Rist
- Web page: https://patentgrep.com/patent/US8772323B2

## CPC

- C07D 413/10: linked by a carbon chain containing aromatic rings
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 413/04: directly linked by a ring-member-to-ring-member bond
- C07D 413/14: containing three or more hetero rings
- C07D 417/14: containing three or more hetero rings
- C07D 453/02: containing not further condensed quinuclidine ring systems
- C07D 498/04: Ortho-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to pyridazinone derivatives of general formula I, wherein the groups A, G and R1 are as defined in the application, the tautomers thereof, stereoisomers thereof, the mixtures thereof and the salts thereof, which have valuable pharmacological properties, and in particular bind to the GPR119 receptor and modulate its activity.

## Claims

### Claim 1

A compound of formula I
wherein:
R1 is hydrogen, 1-4C-alkyl, 3-7C-cycloalkyl, 3-7C-cycloalkyl-1-4C-alkyl, 2-4C-alkenyl,2-4C-alkynyl, 1-4C-alkoxy, 1-4C-alkoxy-1-4C-alkyl, wholly or partially fluorine substituted 1-4C-alkyl, or wholly or partially fluorine substituted 1-4C-alkoxy,
A is CR2R3, O, S, or NR2, wherein R2 is a group selected from hydrogen,1-4C-alkyl, 3-7C-cycloalkyl, 3-7C-cycloalkyl-1-4C-alkyl, 2-4C-alkenyl, 2-4C-alkynyl, 1-4C-alkoxy, 1-4C-alkoxy-1-4C-alkyl, wholly or partially fluorine substituted 1-4C-alkyl, or wholly or partially fluorine substituted 1-4C-alkoxy, or R1 and R2 together represent a bond, or a 1-7C-alkanediyl group wherein one or two —CH2— groups are optionally replaced by —O—, and R3 is hydrogen or 1-4C-alkyl, and
G is a bicyclic system G1or G2:
wherein:
R4 is a group optionally substituted by one to four R5 and/or R6,each independently selected from 1-4C-alkyl, 3-7C-cycloalkyl, 3-7C-cycloalkyl-1-4C-alkyl, 2-4C-alkenyl, 2-4C-alkynyl, aryl, heteroaryl, aryl-1-4C-alkyl, heteroaryl-1-4C-alkyl, heterocyclyl, and heterocyclyl-1-4C-alkyl, wherein:
each R5 independently is hydrogen or a group optionally substituted by one to four R10 and/or R11 and/or R12, each independently selected from 1-4C-alkyl, 3-7C-cycloalkyl, 3-7C-cycloalkyl-1-4C-alkyl, 2-4C-alkenyl, 2-4C-alkynyl, aryl, heteroaryl, heterocyclyl, aryl-1-4C-alkyl, heteroaryl-1-4C-alkyl, and heterocyclyl-1-4C-alkyl, and
each R6 independently is hydrogen or a group selected from: halogen,trifluoromethyl, cyano, oxo, —OR7, —N(R7)R8, —SR7, —C(O)OR7, —C(O)N(R7)R8, —S(O)2N(R7)R8, —C(O)R9, —S(O)2R9, —S(O)R9, —N(R81)C(O)OR7, —N(R81)C(O)N(R7)R8, —N(R81)S(O)2N(R7)R8, —N(R81)C(O)R9, —N(R81)S(O)2R9, and —N(R81)S(O)R9,
wherein:
each R7 independently is hydrogen or a group optionally substituted by one to four R10 and/or R11 and/or R12, each independently selected from 1-4C-alkyl, 3-7C-cycloalkyl, 3-7C-cycloalkyl-1-4C-alkyl, 2-4C-alkenyl, 2-4C-alkynyl, aryl, heteroaryl, heterocyclyl, aryl-1-4C-alkyl, heteroaryl-1-4C-alkyl, and heterocyclyl-1-4C-alkyl,
each R8 independently is hydrogen or a group selected from 1-4C-alkyl and 3-7C-cycloalkyl, or R7 and R8 together represent a 1-9C-alkanediyl group wherein optionally one or two —CH2— groups may each be replaced by —O, —NR81, —S, —SO or —SO2—, wherein each R81 independently is hydrogen or 1-4C-alkyl,
each R9 independently is a group optionally substituted by one to four R10 and/or R11 and/or R12, each independently selected from 1-4C-alkyl, 3-7C-cycloalkyl, 3-7C-cycloalkyl-1-4C-alkyl, aryl, heteroaryl, heterocyclyl, aryl-1-4C-alkyl, heteroaryl-1-4C-alkyl, and heterocyclyl-1-4C-alkyl,
each R10 independently is a group selected from hydrogen, 1-4C-alkyl, 3-7C-cycloalkyl, 3-7C-cycloalkyl-1-4C-alkyl, aryl, heteroaryl, heterocyclyl, aryl-14C-alkyl, heteroaryl-1-4C-alkyl, and heterocyclyl-1-4C-alkyl,
each R11 independently is hydrogen or a group selected from halogen, trifluoromethyl, cyano, oxo, —OR13, —N(R13)R14, and —SR13,
each R12 independently is hydrogen or a group selected from —C(O)OR13, —C(O)N(R13)R14, —S(O)2N(R13)R14, —C(O)R15, —S(O)2R15—S(O)R15, —N(R141)C(O)OR13, —N(R141)C(O)N(R13)R14, —N(R141)S(O)2N(R13)R14, —N(R141)C(O)R15, —N(R141)S(O)2R15, and —N(R141)S(O)R15,
each R13 independently is a group selected from hydrogen, 1-4C-alkyl, 3-7C-cycloalkyl, 3-7C-cycloalkyl-1-4C-alkyl, aryl, heteroaryl, heterocyclyl, aryl-1-4C-alkyl, heteroaryl-1-4C-alkyl, and heterocyclyl-1-4C-alkyl,
each R14 independently is a group selected from hydrogen, 1-4C-alkyl, and 3-7C-cycloalkyl, or R13 and R14 together represent a 1-9C-alkanediyl group wherein optionally one or two —CH2— groups are each replaced by —O, —NR141, —S, —SO, or —SO2—, wherein each R141 independently is hydrogen or 1-4C-alkyl, and
each R15 independently is a group selected from 1-4C-alkyl, 3-7C-cycloalkyl, 3-7C-cycloalkyl-1-4C-alkyl, aryl, heteroaryl, heterocyclyl, aryl-1-4C-alkyl, heteroaryl-1-4C-alkyl, and heterocyclyl-1-4C-alkyl,
wherein:
aryl, on its own or as part of another group, is a carbocyclic aromatic monocyclic ring system containing 6 carbon atoms, which is optionally annelated to a second 5- or 6-membered carbocyclic aromatic, saturated or unsaturated ring system,
heteroaryl, on its own or as part of another group, is a 5-to 12-membered, aromatic, monocyclic or condensed-polycyclic ring system containing 1 to 4 heteroatoms independently selected from N, O, and S(O)r with r=0, 1, or 2, wherein at least one of the heteroatoms is part of the aromatic ring, and
heterocyclyl, on its own or as part of another group, a 3- to 12-membered, saturated, unsaturated or aromatic, monocyclic or condensed, bridged or spiro-polycyclic ring system containing 1 to 4 heteroatoms independently selected from N, O, and S(O)r with r=0, 1, or 2, wherein none of the heteroatoms is part of the aromatic ring,
or a tautomer, enantiomer, or a salt thereof.

### Claim 2 (depends on 1)

The compound of formula I according to claim 1, wherein:
R1 is hydrogen, 1-4C-alkyl, or 1-4C-alkoxy,
A is CR2R3, O, S, or NR2, wherein R2 is a group selected from hydrogen, 1-4C-alkyl and 2-4C-alkenyl, or R1 and R2 together represent a bond or a 1-4C-alkanediyl group, and R3 is hydrogen, and
R4 is a phenyl group optionally independently substituted by one or two R5 and/or R6, wherein:
each R5 independently is hydrogen or a group optionally substituted by one to four, preferably one or two, R10 and/or R11 and/or R12, each independently selected from 1-4C-alkyl, 2-4C-alkenyl, heterocyclyl, phenyl-1-4C-alkyl, and heterocyclyl-1-4C-alkyl,
each R6 independently is hydrogen or a group selected from: halogen, cyano, —OR7, and —N(R7)R8 each R7 independently is hydrogen or a group optionally substituted by one to four R10 and/or R11 and/or R12, each independently selected from 1-4C-alkyl, 2-4C-alkenyl, 2-4C-alkenyl, 3-7C-cycloalkyl, 3-7C-cycloalkyl-1-4C-alkyl, phenyl, heterocyclyl, phenyl-1-4C-alkyl, heteroaryl-1-4C-alkyl, and heterocyclyl-1-4C-alkyl,
each R8 independently is hydrogen or 1-4C-alkyl,
or R7 and R8 together represent a 1-7C-alkanediyl group wherein one or two —CH2— groups each are optionally replaced by —O, —NR81, —S, —SO, or —SO2—, wherein each R81 independently is hydrogen or 1-4C-alkyl, wherein
each R10 independently is a group selected from hydrogen, 1-4C-alkyl, and heterocyclyl,
each R11 independently is hydrogen or a group selected from halogen, cyano, oxo, —OR13, and —N(R13)R14,
each R12 independently is hydrogen or a group selected from C(O)OR13, —C(O)N(R13)R14—C(O)R15, and —S(O)2R15, wherein
each R13 independently is a group selected from hydrogen and 1-4C-alkyl,
each R14 independently is a group selected from hydrogen and 1-4C-alkyl,
or R13 and R14 together represent a 1-7C-alkanediyl group wherein one or two —CH2— groups each are optionally replaced by —O, —NR141, —S, —SO, or —SO2—, wherein each R141 independently is hydrogen or 1-4C-alkyl,
each R15 independently is a group selected from 1-4C-alkyl,
wherein heteroaryl, on its own or as part of another group, is a 5- or 6-membered aromatic, monocyclic ring system containing 1 to 3 heteroatoms independently selected from N, O, and S, and
heterocyclyl, on its own or as part of another group, is a 3- to 12-membered, saturated, monocyclic or bridged or spiro-bicyclic ring system containing 1 or 2 heteroatoms independently selected from N, O, and S(O)r with r=0, 1, or 2;
or a tautomer, enantiomer, or a salt thereof.

### Claim 3 (depends on 1)

The compound of formula I according to claim 1, wherein:
R1 is 1-4C-alkyl,
A is CR2R3, O, S, or NH, wherein R2 is a group selected from hydrogen and 1-4C-alkyl, or R1 and R2 together represent a 1-2C-alkanediyl group, and R3 is hydrogen, and
R4 is a phenyl group optionally independently substituted by one or two R5 and/or R6,
wherein each R5 independently is hydrogen, 1-4C-alkyl, or heterocyclyl,
wherein each R6 independently is hydrogen or a group selected from: halogen, cyano,—OR7, and —N(R7)R8,
wherein each R7 independently is a group selected from hydrogen, 1-4C-alkyl, 3-7C-cycloalkyl, 3-7C-cycloalkyl-1-4C-alkyl, H2N-2-4C-alkyl, mono-or di-(1-4C-alkylamino)-2-4C-alkyl, 1-4C-alkoxy-2-4C-alkyl, hydroxy-2-4C-alkyl, 1-4C-alkoxycarbonyl-1-4C-alkyl, phenyl, heterocyclyl, benzyl, 2-phenylethyl, heteroaryl-1-4C-alkyl, and heterocyclyl-1-4C-alkyl,
wherein 3-7C-cycloalkyl, on its own or as part of another group, is optionally substituted by a hydroxy, mono-or di-1-4C-alkylamino, or heterocyclyl,
each R8 independently is hydrogen or 1-4C-alkyl,
or R7 and R8 together represent a 1-7C-alkanediyl group wherein one or two —CH2— groups each are optionally replaced by —O, —NR81, —S, —SO, or —SO2—, wherein each R81 independently is hydrogen or 1-4C-alkyl,
wherein heteroaryl, on its own or as part of another group, is a 5- or 6-membered aromatic, monocyclic ring system containing 1 to 3 heteroatoms independently selected from N, O, and S, each optionally independently substituted by one or two halogen and/or 1-4C-alkyl, and
heterocyclyl, on its own or as part of another group, is a 3- to 12-membered, saturated, monocyclic or bridged or spiro-bicyclic ring system containing 1 or 2 heteroatoms independently selected from N, O, and S(O)r with r=0, 1, or 2, which are each optionally independently substituted by one to four, halogen, cyano, 1-4C-alkoxycarbonyl, and/or 1-4C-alkyl,
or a tautomer, enantiomer, or a salt thereof.

### Claim 4 (depends on 1)

The compound of formula I according to claim 1, wherein:
R1 is 1-4C-alkyl,
A is CR2R3, O, S, or NH, wherein R2 is a group selected from 1-4C-alkyl, or R1 and R2 together represent a 1-2C-alkanediyl group, and R3 is hydrogen, and
R4 is a group optionally independently substituted by one or two R5 and/or R6 selected from phenyl and heteroaryl, wherein
each R5 independently is hydrogen, 1-4C-alkyl, or heterocyclyl, wherein
each R6 independently is hydrogen or a group selected from halogen, cyano, —OR7, and —N(R7)R8, wherein
each R7 independently is a group selected from hydrogen, 1-4C-alkyl, 3-7C-cycloalkyl, 3-7C-cycloalkyl-1-4C-alkyl, H2N-2-4C-alkyl, mono- or di-(1-4C-alkylamino)-2-4C-alkyl, 1-4C-alkoxy-2-4C-alkyl, hydroxy-2-4C-alkyl, 1-4C-alkoxycarbonyl-1-4C-alkyl, phenyl, heterocyclyl, benzyl, 2-phenylethyl, heteroaryl-1-4C-alkyl and heterocyclyl-1-4C-alkyl,
wherein 3-7C-cycloalkyl, on its own or as part of another group, is optionally substituted by a hydroxy, mono-or di-1-4C-alkylamino, or heterocyclyl,
each R8 independently is hydrogen or 1-4C-alkyl,
or R7 and R8 together represent a 1-7C-alkanediyl group wherein one or two —CH2— groups each are optionally replaced by —O, —NR81, —S, —SO, or —SO2—, wherein each R81 independently is hydrogen or 1-4C-alkyl,
wherein heteroaryl, on its own or as part of another group, is a 5- or 6-membered aromatic, monocyclic ring system containing 1 to 3 heteroatoms independently selected from N, O, and S, each optionally independently substituted by one or two halogen and/or 1-4C-alkyl, and
heterocyclyl, on its own or as part of another group, is a 3- to 12-membered, saturated, monocyclic or bridged or spiro-bicyclic ring system containing 1 or 2 heteroatoms independently selected from N, O, and S(O)r with r=0, 1, or 2, each optionally independently substituted by one to four halogen, cyano, 1-4C-alkoxycarbonyl, and/or 1-4C-alkyl,
or a tautomer, enantiomer, or a salt thereof.

### Claim 5 (depends on 1)

The compounds of formula I according to claim 1, wherein:
R1 is 1-4C-alkyl,
A is CR2R3, O, S, or NH, wherein R2 is a group selected from hydrogen and 1-4C-alkyl, or R1 and R2 together represent a 1-2C-alkanediyl group, and R3 is hydrogen, and
G is G1
wherein:
R4 is a phenyl group optionally independently substituted by R6 and/or one or two halogen or 1-2C-alkyl,
R6 is —OR7,
wherein the phenyl group carries the substituent R6 in the meta or para position, relative to the point of attachment of the phenyl group to the system G1,
wherein each R7 independently is a group selected from hydrogen, 1-4C-alkyl, 3-7C-cycloalkyl, 3-7C-cycloalkyl-1-4C-alkyl, di-(1-4C-alkylamino)-2-4C-alkyl, 1-4C-alkoxy-2-4C-alkyl, hydroxy-2-4C-alkyl, 1-4C-alkoxycarbonyl-1-4C-alkyl, phenyl, heterocyclyl, benzyl, 2-phenylethyl, heteroaryl-1-4C-alkyl, and heterocyclyl-1-4C-alkyl,
wherein 3-7C-cycloalkyl, on its own or as part of another group is optionally substituted by a hydroxy, di-1-4C-alkylamino, piperidin-1-yl, pyrrolidin-1-yl, or morpholin-1-yl,
wherein heteroaryl, on its own or as part of another group, is a 5- or 6-membered aromatic, monocyclic ring system containing 1 to 3 heteroatoms independently selected from N, O, and S, each optionally independently substituted by one or two halogen and/or 1-4C-alkyl, and
heterocyclyl, on its own or as part of another group, is a 3- to 12-membered, saturated, monocyclic or bridged or spiro-bicyclic ring system containing 1 or 2 heteroatoms independently selected from N, O, and S(O)r with r=0, 1, or 2,each optionally independently substituted by one to four, halogen, cyano, 1-4C-alkoxycarbonyl, and/or 1-4C-alkyl,
or a tautomer, enantiomer, or a salt thereof.

### Claim 6 (depends on 1)

A physiologically acceptable salt of a compound of formula I according to claim 1.

### Claim 7 (depends on 1)

The compound according to claim 1, excluding each of the compounds:
5-methyl-6-[2-(3-thienyl)-benzoxazol-6-yl]-4,5-dihydro-3(2H)-pyridazinone,
5-methyl-6-[2-(2-pyridyl)-benzoxazol-6-yl]-4,5-dihydro-3(2H)-pyridazinone,
5-methyl-6-[2-(2-furyl)-benzoxazol-6-yl]-4,5-dihydro-3(2H)-pyridazinone,
5-methyl-6-[2-(2-thienyl)-benzoxazol-6-yl]-4,5-dihydro-3(2H)-pyridazinone,
5-methyl-6-[2-(3-pyridyl)-benzoxazol-6-yl]-4,5-dihydro-3(2H)-pyridazinone,
5-methyl-6-[2-(2-pyrazinyl)-benzoxazol-6-yl]-4,5-dihydro-3(2H)-pyridazinone,
5-methyl-6-[2-(4-pyridyl)-benzoxazol-6-yl]-4,5-dihydro-3(2H)-pyridazinone,
5-methyl-6-[2-(1-acetyl-piperidino)-benzoxazol-6-yl]-4,5-dihydro-3(2H)-pyridazinone,
5-methyl-6-[2-(4-methyl-5-oxazolyl)-benzoxazol-6-yl]-4,5-dihydro-3(2H)-pyridazinone,
5-methyl-6-[2-(5-pyrimidinyl)-benzoxazol-6-yl]-4,5-dihydro-3(2H)-pyridazinone,
5-methyl-6-[2-(2-amino-5-pyridyl)-benzoxazol-6-yl]-4,5-dihydro-3(2H)-pyridazinone,
6-[2-(2-pyridyl)-benzoxazol-6-yl]-4,5-dihydro-3(2H)-pyridazinone,
6-[2-(2-furyl)-benzoxazol-6-yl]-4,5-dihydro-3(2H)-pyridazinone,
5-methyl-6-[2-(4-thiomorpholino)-benzoxazol-6-yl]-4,5-dihydro-3(2H)-pyridazinone,
5-methyl-6-[2-(1-piperidino)-benzoxazol-6-yl]-4,5-dihydro-3(2H)-pyridazinone,
5-methyl-6-[2-(1-oxido-4-thiomorpholino)-benzoxazol-6-yl]-4,5-dihydro-3(2H)-pyridazinone,
5-methyl-6-[2-(1,1-dioxido-4-thiomorpholino)-benzoxazol-6-yl]-4,5-dihydro-3(2H)-pyridazinone,
5-methyl-6-[2-(4-methyl-1-piperazinyl)-benzoxazol-6-yl]-4,5-dihydro-3(2H)-pyridazinone,
5-methyl-6-[2-(4-carbethoxy-1-piperazinyl)-benzoxazol-6-yl]-4,5-dihydro-3(2H)-pyridazinone,
5-methyl-6-[2-(1-pyrrolidinyl)-benzoxazol-6-yl]-4,5-dihydro-3(2H)-pyridazinone,
5-methyl-6-[2-(1-piperazinyl)-benzoxazol-6-yl]-4,5-dihydro-3(2H)-pyridazinone,
5-methyl-6-[2-(4-methyl-1-imidazolyl)-benzoxazol-6-yl]-4,5-dihydro-3(2H)-pyridazinone,
6-[2-(1-piperidino)-benzoxazol-6-yl]-4,5-dihydro-3(2H)-pyridazinone,
6-[2-(4-morpholino)-benzoxazol-6-yl]-4,5-dihydro-3(2H)-pyridazinone,
6-[2-(1-pyrrolidinyl)-benzoxazol-6-yl]-4,5-dihydro-3(2H)-pyridazinone,
6-[2-(4-methyl-1-imidazolyl)-benzoxazol-6-yl]-4,5-dihydro-3(2H)-pyridazinone,
6-[2-(4-carbethoxy-1-piperazinyl)-benzoxazol-6-yl]-4,5-dihydro-3(2H)-pyridazinone,
6-[2-(1-piperazinyl)-benzoxazol-6-yl]-4,5-dihydro-3(2H)-pyridazinone,
6-[2-(1-oxido-4-thiomorpholino)-benzoxazol-6-yl]-4,5-dihydro-3(2H)-pyridazinone,
6-[2-(1,1-dioxido-4-thiomorpholino)-benzoxazol-6-yl]-4,5-dihydro-3(2H)-pyridazinone,
6-[2-(4-methyl-1-piperazinyl)-benzoxazol-6-yl]-4,5-dihydro-3(2H)-pyridazinone,
6-[2-(4-thiomorpholino)-benzoxazol-6-yl]-4,5-dihydro-3(2H)-pyridazinone,
5-methyl-6-[2-(1-imidazolyl)-benzoxazol-6-yl]-4,5-dihydro-3(2H)-pyridazinone,
5-methyl-6-[2-(4-morpholino)-benzoxazol-6-yl]-4,5-dihydro-3(2H)-pyridazinone,
6-[2-(3-thienyl)-benzoxazol-6-yl]-4,5-dihydro-3(2H)-pyridazinone,
5-methyl-6-[2-(2-acetamido-5-pyridyl)-benzoxazol-6-yl]-4,5-dihydro-3(2H)-pyridazinone,
5-methyl-6-[2-(2,6-dichloro-3-pyridyl)-benzoxazol-6-yl]-4,5-dihydro-3(2H)-pyridazinone and
5-methyl-6-[2-(2-chloro-6-morpholino-3-pyridyl) benzoxazol-6-yl]-4,5-dihydro-3(2H)-pyridazinone.

### Claim 8 (depends on 1)

A compound according to claim 1 selected from the following:
(5S)-5-methyl-6-(2-phenyl-1,3-benzoxazol-6-yl)-2,3,4,5-tetrahydropyridazin-3-one,
(4S)-4-methyl-6-(2-phenyl-1,3-benzoxazol-6-yl)-2,3,4,5-tetrahydropyridazin-3-one,
(5R)-5-methyl-6-(2-phenyl-1,3-benzoxazol-6-yl)-2,3,4,5-tetrahydropyridazin-3-one,
(4R)-4-methyl-6-(2-phenyl-1,3-benzoxazol-6-yl)-2,3,4,5-tetrahydropyridazin-3-one,
5-(2-phenyl-1,3-benzoxazol-6-yl)-3,4-diazabicyclo[4.1.0]hept-4-en-2-one,
5-(7-methyl-2-phenyl-1,3-benzoxazol-6-yl)-3,4-diazabicyclol[4.1.0]hept-4-en-2-one,
6-(2-phenyl-1,3-benzoxazol-6-yl)-4-(prop-2-en-1-yl)-2,3,4,5-tetrahydropyridazin-3-one,
6-(2-phenyl-1,3-benzoxazol-6-yl)-5-propyl-2,3,4,5-tetrahydropyridazin-3-one,
6-(2-phenyl-1,3-benzoxazol-6-yl)-4-propyl-2,3,4,5-tetrahydropyridazin-3-one,
5-(2-phenyl-1,3-benzoxazol-6-yl)-3,4-diazabicyclol[4.2.0]oct-4-en-2-one,
5-(4-methyl-2-phenyl-1,3-benzoxazol-6-yl)-3,4-diazabicyclol[4.1.0]hept-4-en-2-one,
5-[2-(3-methylphenyl)-1,3-benzoxazol-6-yl]-3,4-diazabicyclol[4.1.01]hept-4-en-2-one,
5-[2-(4-methylphenyl)-1,3-benzoxazol-6-yl]3,4-diazabicyclo [4.1.0]hept-4-en-2-one,
5-[2-(3,4-dimethylphenyl)-1,3-benzoxazol-6-yl]-3,4-diazabicyclo[4.1.0]hept-4-en-2-one,
5-{2-[4-(piperidin-1-ylmethyl)phenyl]-1,3-benzoxazol-6-yl}-3,4-diazabicyclo[4.1.0]hept-4-en-2-one,
6-(2-phenyl-1,3-benzoxazol-6-yl)-2,3,4,5-tetrahydropyridazin-3-one,
5-[2-(3-fluorophenyl)-1,3-benzoxazol-6-yl]-3,4-diazabicyclo[4.1.0]hept-4-en-2-one,
5-[2-(4-fluorophenyl)-1,3-benzoxazol-6-yl]-3,4-diazabicyclo[4.1.0]hept-4-en-2-one,
5-[2-(4-fluorophenyl)-1,3-benzoxazol-6-yl]-3,4-diazabicyclo[4.2.0]oct-4-en-2-one,
5-[2-(2-fluorophenyl)-1,3-benzoxazol-6-yl]-3,4-diazabicyclo[4.1.0]hept-4-en-2-one,
4.4-dimethyl-6-(2-phenyl-1,3-benzoxazol-6-yl)-2,3,4,5-tetrahydropyridazin-3-one,
5-{2-[4-(morpholin-4-ylmethyl)phenyl]-1,3-benzoxazol-6-yl}-3,4-diazabicyclo[4.1.0]hept-4-en-2-one,
tert-butyl 4-{[4-(6-{5-oxo-3,4-diazabicyclo[4.1.0]hept-2-en-2-yl}-1,3-benzoxazol-2-yl)phenyl]methyl}piperazine-1-carboxylate,
(4S,5R)-4,5-dimethyl-6-[2-(5-methylthiophen-2-yl)-1,3-benzoxazol-6-yl]-2,3,4,5-tetrahydropyridazin-3-one,
(4R,5S)-4,5-dimethyl-6-(2-phenyl-1,3-benzoxazol-6-yl)-2,3,4,5-tetrahydropyridazin-3-one,
(4S,5S)-4,5-dimethyl-6-(2-phenyl-1,3-benzoxazol-6-yl)-2,3,4,5-tetrahydropyridazin-3-one,
(5R)-5-methoxy-6-(2-phenyl-1,3-benzoxazol-6-yl)-2,3,4,5-tetrahydropyridazin-3-one,
(5S)-5-methoxy-6-(2-phenyl-1,3-benzoxazol-6-yl)-2,3,4,5-tetrahydropyridazin-3-one,
5-ethyl-6-(2-phenyl-1,3-benzoxazol-6-yl)-2,3,4,5-tetrahydropyridazin-3-one,
(5S)-5-ethyl-6-(2-phenyl-1,3-benzoxazol-6-yl)-2,3,4,5-tetrahydropyridazin-3-one,
(5R)-5-ethyl-6-(2-phenyl-1,3-benzoxazol-6-yl)-2,3,4,5-tetrahydropyridazin-3-one,
6-(2-phenyl-1,3-benzoxazol-6-yl)-5-(propan-2-yl)-2,3,4,5-tetrahydropyridazin-3-one,
6-{2-[4-(benzyloxy)phenyl]-1,3-benzoxazol-6-yl}-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one,
6-{2-[3-(benzyloxy)phenyl]-1,3-benzoxazol-6-yl}-5-methyl-2,3,4,5-tetrahydropyridazin-3-one,
6{2-[3-(benzyloxy)phenyl]-1,3-benzoxazol-6-yl}-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one,
6{2-[4-(benzyloxy)phenyl]-1,3-benzoxazol-6-yl}-5-methyl-2,3,4,5-tetrahydropyridazin-3-one,
5-ethyl-6-[2-(4-hydroxyphenyl)-1,3-benzoxazol-6-yl]-2,3,4,5-tetrahydropyridazin-3-one,
6-[2-(3-hydroxyphenyl)-1,3-benzoxazol-6-yl]-5-methyl-2,3,4,5-tetrahydropyridazin-3-one,
5-ethyl-6-[2-(3-hydroxyphenyl)-1,3-benzoxazol-6-yl]-2,3,4,5-tetrahydropyridazin-3-one,
5-ethyl-6-{2-[4-(pyrimidin-2-ylmethoxy)phenyl]-1,3-benzoxazol-6-yl}-2,3,4,5-tetrahydropyridazin-3-one,
2-{4-[6-(4-ethyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl)-1,3-benzoxazol-2-yl]phenoxy}-N,N-dimethylacetamide,
5-ethyl-6-(2-{4-[(1-methyl-1H-imidazol-5-yl)methoxy]phenyl}-1,3-benzoxazol-6-yl)-2,3,4,5-tetrahydropyridazin-3-one,
2-{4-[6-(4-ethyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl)-1,3-benzoxazol-2-yl]phenoxyl}-N-methylacetamide,
5-ethyl-6-(2-{4-[2-(4-methylpiperazin-1-yl)ethoxy]phenyl}-1,3-benzoxazol-6-yl)-2,3,4,5-tetrahydropyridazin-3-one,
5-ethyl-6-{2-[3-(pyridin-3-ylmethoxy)phenyl]-1,3-benzoxazol-6-yl}-2,3,4,5-tetrahydropyridazin-3-one,
5-ethyl-6-{2-[4-(pyridin-4-ylmethoxy)phenyl]-1,3-benzoxazol-6-yl}-2,3,4,5-tetrahydropyridazin-3-one,
5-ethyl-6-{2-[4-(pyridin-2-ylmethoxy)phenyl]-1,3-benzoxazol-6-yl}-2,3,4,5-tetrahydropyridazin-3-one,
5-ethyl-6-{2-[4-(thiophen-3-ylmethoxy)phenyl]-1,3-benzoxazol-6-yl}-2,3,4,5-tetrahydropyridazin-3-one,
5-ethyl-6-(2-{4-[2-(piperidin-1-yl)ethoxy]phenyl}1,3-benzoxazol-6-yl)-2,3,4,5-tetrahydropyridazin-3-one,
5-ethyl-6-[2-(4-{[3-(propan-2-yl)-1,2,4-oxadiazol-5-yl]methoxy}phenyl)-1,3-benzoxazol-6-yl]-2,3,4,5-tetrahydropyridazin-3-one,
5-ethyl-6-{2-[4-(thiophen-2-ylmethoxy)phenyl]-1,3-benzoxazol-6-yl}-2,3,4,5-tetrahydropyridazin-3-one,
5-ethyl-6-[2-(4-propoxyphenyl)-1,3-benzoxazol-6-yl]-2,3,4,5-tetrahydropyridazin-3-one,
6-(2-{4-[2-(azepan-1-yl)ethoxy]phenyl}-1,3-benzoxazol-6-yl)-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one,
6-{2-[4-(cyclohexylmethoxy)phenyl]-1,3-benzoxazol-6-yl}-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one,
6-(2-{4-[2-(dimethylamino)ethoxy]phenyl}-1,3-benzoxazol-6-yl)-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one,
6-{2-[4-(2-cyclohexylethoxy)phenyl]-1,3-benzoxazol-6-yl}-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one,
6-[2-(4-{2-[bis(propan-2-yl)amino]ethoxy}phenyl)-1,3-benzoxazol-6-yl]-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one,
5-ethyl-6-(2-{4-[2-(2,2,6,6tetramethylpiperidin-1-yl)ethoxy]phenyl}-1,3-benzoxazol-6-yl)-2,3,4,5-tetrahydropyridazin-3-one,
5-ethyl-6-{2-[4-(pyrimidin-5-ylmethoxy)phenyl]-1,3-benzoxazol-6-yl}-2,3,4,5-tetrahydropyridazin-3-one,
5-ethyl-6-{2-[4-(pyridin-3-ylmethoxy)phenyl]-1,3-benzoxazol-6-yl}-2,3,4,5-tetrahydropyridazin-3-one,
5-ethyl-6-(2-{4-[2-oxo-2-(piperidin-1-yl)ethoxy]phenyl}-1,3-benzoxazol-6-yl)-2,3,4,5-tetrahydropyridazin-3-one,
6-(2-{4-[3-(dimethylamino)propoxy]phenyl}-1,3-benzoxazol-6-yl)-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one,
5-ethyl-6{-2-[4-(1,3-oxazol-5-ylmethoxy)phenyl]-1,3-benzoxazol-6-yl}-2,3,4,5-tetrahydropyridazin-3-one,
5-ethyl-6-(2-{4-[2-(morpholin-4-yl)ethoxy]phenyl}-1,3-benzoxazol-6-yl)-2,3,4,5-tetrahydropyridazin-3-one,
5-ethyl-6{-2-[3-(pyridin-2-ylmethoxy)phenyl]-1,3-benzoxazol-6-yl}-2,3,4,5-tetrahydropyridazin-3-one,
tert-butyl 2-{4-[6-(4-ethyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl)-1,3-benzoxazol-2-yl]phenoxy}acetate,
tert-butyl 4-{4-[6-(4-ethyl-6-oxo-1,4,5,6tetrahydropyridazin-3-yl)-1,3-benzoxazol-2-yl]phenoxymethyl}piperidine-1-carboxylate,
tert-butyl 4-{4-[6-(4-ethyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl)-1,3-benzoxazol-2-yl]phenoxyl}piperidine-1-carboxylate,
tert-butyl 4-{3-[6-(4-methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl)-1,3-benzoxazol-2-yl]phenoxymethyl}piperidine-1-carboxylate,
2-{4-[6-(4-ethyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl)-1,3-benzoxazol-2-yl]phenoxy}acetic acid,
5-ethyl-6-{2-[4-(piperidin-4-ylmethoxy)phenyl]-1,3-benzoxazol-6-yl}-2,3,4,5-tetrahydropyridazin-3-one,
5-ethyl-6-{2-[4-(piperidin-4-yloxy)phenyl]-1,3-benzoxazol-6-yl}-2,3,4,5-tetrahydropyridazin-3-one,
5-methyl-6-{2-[3-(piperidin-4-ylmethoxy)phenyl]-1,3-benzoxazol-6-yl}-2,3,4,5-tetrahydropyridazin-3-one,
5-ethyl-6-(2-{4-[(1-methanesulphonylpiperidin-4-yl)methoxy]phenyl}-1,3-benzoxazol-6-yl)-2,3,4,5-tetrahydropyridazin-3-one,
5-ethyl-6-(2-{4-[(E)-2-phenylethenyl]phenyl}-1,3-benzoxazol-6-yl)-2,3,4,5-tetrahydropyridazin-3-one,
5-ethyl-6-{2-[4-(2-phenylethyl)phenyl]-1,3-benzoxazol-6-yl}-2,3,4,5-tetrahydropyridazin-3-one,
6-ethyl-5-(2-phenyl-1,3-benzoxazol-6-yl)-3,6-dihydro-2H-1,3,4-thiadiazin-2-one,
6-ethyl-5-(2-phenyl-1,3-benzoxazol-6-yl)-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,
(6R)-6-ethyl-5-(2-phenyl-1,3-benzoxazol-6-yl)-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,
(6S)-6-ethyl-5-(2-phenyl-1,3-benzoxazol-6-yl)-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,
6-methyl-5-(2-phenyl-1,3-benzoxazol-6-yl)-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,
5-methyl-6-(2-phenyl-1,3-benzoxazol-6-yl)-2,3,4,5-tetrahydropyridazin-3-one,
6-[2-(4-methoxyphenyl)-1,3-benzoxazol-6-yl]-5-methyl-2,3,4,5-tetrahydropyridazin-3-one,
6-[2-(4-chlorophenyl)-1,3-benzoxazol-6-yl]-5-methyl-2,3,4,5-tetrahydropyridazin-3-one,
6-[2-(3-methoxyphenyl)-1,3-benzoxazol-6-yl]-5-methyl-2,3,4,5-tetrahydropyridazin-3-one,
6-[2-(2-methoxyphenyl)-1,3-benzoxazol-6-yl]-5-methyl-2,3,4,5-tetrahydropyridazin-3-one,
5-methyl-6-[2-(5-methylthiophen-2-yl)-1,3-benzoxazol-6-yl]-2,3,4,5-tetrahydropyridazin-3-one,
6-[2-(3-chlorophenyl)-1,3-benzoxazol-6-yl]-5-methyl-2,3,4,5-tetrahydropyridazin-3-one,
6-[2-(2-chlorophenyl)-1,3-benzoxazol-6-yl]-5-methyl-2,3,4,5-tetrahydropyridazin-3-one,
methyl 4-[6-(4-methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl)-1,3-benzoxazol-2-yl]benzoate,
5-ethyl-6-[2-(2-fluoro-4-methoxyphenyl)-1,3-benzoxazol-6-yl]-2,3,4,5-tetrahydropyridazin-3-one,
6-[2-(3 ,4-dimethoxyphenyl)-1,3-benzoxazol-6-yl]-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one,
5-ethyl-6-[2-(4-fluoro-3-methoxyphenyl)-1,3-benzoxazol-6-yl]-2,3,4,5-tetrahydropyridazin-3-one,
6-[2-(4-ethoxyphenyl)-1,3-benzoxazol-6-yl]-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one,
5-ethyl-6-[2-(4-phenoxyphenyl)-1,3-benzoxazol-6-yl]-2,3,4,5-tetrahydropyridazin-3-one,
6-{2-[4-(dimethylamino)phenyl]-1,3-benzoxazol-6-yl}-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one
5-ethyl-6-[2-(4-methylthiophen-2-yl)-1,3-benzoxazol-6-yl]-2,3,4,5-tetrahydropyridazin-3-one,
5-ethyl-6-[2-(3-fluoro-4-methoxyphenyl)-1,3-benzoxazol-6-yl]-2,3,4,5-tetrahydropyridazin-3-one,
5-ethyl-6-{2-[4-(propan-2-yloxy)phenyl]-1,3-benzoxazol-6-yl}-2,3,4,5-tetrahydropyridazin-3-one,
5-ethyl-6-{2-[3-(propan-2-yloxy)phenyl]-1,3-benzoxazol-6-yl}-2,3,4,5-tetrahydropyridazin-3-one,
5-ethyl-6-[2-(5-methylthiophen-2-yl)-1,3-benzoxazol-6-yl]-2,3,4,5-tetrahydropyridazin-3-one,
5-ethyl-6-[2-(3-methoxyphenyl)-1,3-benzoxazol-6-yl]-2,3,4,5-tetrahydropyridazin-3-one,
5-ethyl-6-{2-[4-(trifluoromethoxy)phenyl]-1,3-benzoxazol-6-yl}-2,3,4,5-tetrahydropyridazin-3-one,
5-ethyl-6-[2-(4-methoxyphenyl)-1,3-benzoxazol-6-yl]-2,3,4,5-tetrahydropyridazin-3-one,
5-ethyl-6-{2-[4-(oxan-4-yloxy)phenyl]-1,3-benzoxazol-6-yl}-2,3,4,5-tetrahydropyridazin-3-one,
5-methyl-6-[2-(thiophen-2-yl)-1,3-benzoxazol-6-yl]-2,3,4,5-tetrahydropyridazin-3-one,
5-methyl-6-[2-(thiophen-3-yl)-1,3-benzoxazol-6-yl]-2,3,4,5-tetrahydropyridazin-3-one,
6-[2-(furan-2-yl)-1,3-benzoxazol-6-yl]-5-methyl-2,3,4,5-tetrahydropyridazin-3-one,
6-[2-(6-aminopyridin-3-yl)-1,3-benzoxazol-6-yl]-5-methyl-2,3,4,5-tetrahydropyridazin-3-one,
5-methyl-6-[2-(pyridin-3-yl)-1,3-benzoxazol-6-yl]-2,3,4,5-tetrahydropyridazin-3-one,
6-[2-(thiophen-2-yl)-1,3-benzoxazol-6-yl]-2,3,4,5-tetrahydropyridazin-3-one,
6-[2-(furan-2-yl)-1,3-benzoxazol-6-yl]-2,3,4,5-tetrahydropyridazin-3-one,
5-methyl-6-[2-(thiomorpholin-4-yl)-1,3-benzoxazol-6-yl]-2,3,4,5-tetrahydropyridazin-3-one,
ethyl 4-[6-(4-methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl)-1,3-benzoxazol-2-yl]piperazine-1-carboxylate,
5-methyl-6[2-(piperidin-1-yl)-1,3-benzoxazol-6-yl]-2,3,4,5-tetrahydropyridazin-3-one,
5-methyl-6-[2-(morpholin-4-yl)-1,3-benzoxazol-6-yl]-2,3,4,5-tetrahydropyridazin-3-one,
5-methyl-6[2-(piperazin-1-yl)-1,3-benzoxazol-6-yl]-2,3,4,5-tetrahydropyridazin-3-one,
6-[2-(piperidin-1-yl)-1,3-benzoxazol-6-yl]-2,3,4,5-tetrahydropyridazin-3-one,
6-[2-(thiomorpholin-4-yl)-1,3-benzoxazol-6-yl]-2,3,4,5-tetrahydropyridazin-3-one,
6-[2-(2,6-dichloropyridin-3-yl)-1,3-benzoxazol-6-yl]-5-methyl-2,3,4,5-tetrahydropyridazin-3-one,
6-{2-[2-chloro-6-(morpholin-4-yl)pyridin-3-yl]-1,3-benzoxazol-6-yl}-5-methyl-2,3,4,5-tetrahydropyridazin-3-one,
4-[6-(4-methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl)-1,3-benzoxazol-2-yl]benzonitrile,
3-[6-(4-methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl)-1,3-benzoxazol-2-yl]benzonitrile,
6-{2-[4-(aminomethyl)phenyl]-1,3-benzoxazol-6-yl}-5-methyl-2,3,4,5-tetrahydropyridazin-3-one,
6-{2-[3-(aminomethyl)phenyl]-1,3-benzoxazol-6-}-5-methyl-2,3,4,5-tetrahydropyridazin-3-one,
(4S,5S)-4-ethyl-5-methyl-6-(2-phenyl-1,3-benzoxazol-6-yl)-2,3,4,5-tetrahydropyridazin-3-one,
(4R,5S)-4-ethyl-5-methyl-6-(2-phenyl-1,3-benzoxazol-6-yl)-2,3,4,5-tetrahydropyridazin-3-one,
(4S,5S)-5-methyl-6-(2-phenyl-1,3-benzoxazol-6-yl)-4-propyl-2,3,4,5-tetrahydropyridazin-3-one,
(4R,5S)-5-methyl-6-(2-phenyl-1,3-benzoxazol-6-yl)-4-propyl-2,3,4,5-tetrahydropyridazin-3-one,
5(2-phenyl-4,5,6,7-tetrahydro-1,3-benzoxazol-6-yl)-3,4-diazabicyclo[4.1.0]hept-4-en-2-one,
(1R,6S)-5-[(6S)-2-phenyl-4,5,6,7-tetrahydro-1,3-benzoxazol-6-yl]-3,4-diazabicyclo[4.1.0]hept-4-en-2-one,
(1R,6S)-5-[(6R)-2-phenyl-4,5,6,7-tetrahydro-1,3-benzoxazol-6-yl]-3,4-diazabicyclo[4.1.0]hept-4-en-2-one,
(1S,6R)-5-[(6S)-2-phenyl-4,5,6,7-tetrahydro-1,3-benzoxazol-6-yl]-3,4-diazabicyclo[4.1.0]hept-4-en-2-one,
(1S,6R)-5-[(6R)-2-phenyl-4,5,6,7-tetrahydro-1,3-benzoxazol-6-yl]-3,4-diazabicyclo[4.1.0]hept-4-en-2-one,
5-(2-benzyl-1,3-benzoxazol-6-yl)-3,4-diazabicyclo[4.1.0]hept-4-en-2-one,
5-(2-{4-[2-(morpholin-4-yl)ethoxy]phenyl}-1,3-benzoxazol-6-yl)-3,4-diazabicyclo[4.1.0]hept-4-en-2-one,
4-methyl-6-[2-(thiophen-2-yl)-1,3-benzoxazol-6-yl]-2,3,4,5-tetrahydropyridazin-3-one,
4-butyl-6-[2-(thiophen-2-yl)-1,3-benzoxazol-6-yl]-2,3,4,5-tetrahydropyridazin-3-one,
4-ethyl-6-[2-(thiophen-2-yl)-1,3-benzoxazol-6-yl]-2,3,4,5-tetrahydropyridazin-3-one,
5-methyl-6-(2-phenyl-1,3-benzoxazol-6-yl)-2,3,4,5-tetrahydro-1,2,4-triazin-3-one,
6-(2-phenyl-1,3-benzoxazol-6-yl)-2,3,4,5-tetrahydro-1,2,4-triazin-3-one,
5-ethyl-6-(2-phenyl-1,3-benzoxazol-6-yl)-2,3,4,5-tetrahydro-1,2,4-triazin-3-one,
(4S ,5S)-5-ethyl-4-methyl-6-(2-phenyl-1,3-benzoxazol-6-yl)-2,3,4,5-tetrahydropyridazin-3-one,
4S ,5R)-5-ethyl-4-methyl-6-(2-phenyl-1,3-benzoxazol-6-yl)-2,3,4,5-tetrahydropyridazin-3-one,
(4R,5R)-5-ethyl-4-methyl-6-(2-phenyl-1,3-benzoxazol-6-yl)-2,3,4,5-tetrahydropyridazin-3-one,
5-ethyl-6-(2-{3-[2-(piperidin-1-yl)ethoxy]phenyl }-1,3-benzoxazol-6-yl)-2,3,4,5-tetrahydropyridazin-3-one,
6-(2-{3-[2-(azepan-1-yl)ethoxy]phenyl }-1,3-benzoxazol-6-yl)-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one,
5-ethyl-6-{2-[3-(pyridin-4-ylmethoxy)phenyl]-1,3-benzoxazol-6-yl}-2,3,4,5-tetrahydropyridazin-3-one,
5-ethyl-6-(2-{3-[2-(2,2,6,6-tetramethylpiperidin-1-yl)ethoxy]phenyl}-1,3-benzoxazol-6-yl)-2,3,4,5-tetrahydropyridazin-3-one,
5-ethyl-6-(2-{3-[3-(piperidin-1-yl)propoxy]phenyl }-1,3-benzoxazol-6-yl)-2,3,4,5-tetrahydropyridazin-3-one,
1-(2-{3-[6-(4-ethyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl)-1,3-benzoxazol-2-yl]phenoxy}ethyl)piperidine-4-carbonitrile,
6-[2-(3-{2-[bis(propan-2-yl)amino]ethoxy}phenyl)-1,3-benzoxazol-6-yl]-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one,
tert-butyl 4-(2-{3-[6-(4-ethyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl)-1,3-benzoxazol-2-yl]phenoxy }ethyl)piperazine-1-carboxylate,
6-[2-(3-{2-[bis(2-methylpropyl)amino]ethoxy}phenyl)-1,3-benzoxazol-6-yl]-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one,
6-[2-3-{2-[4-(butan-2-yl)piperazin-1-yl]ethoxy}phenyl)-1,3-benzoxazol-6-yl]-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one,
5-ethyl-6-(2-{4-[(4-methanesulphonylphenyl)methoxyl]phenyl}-1,3-benzoxazol-6-yl)-2,3,4,5-tetrahydropyridazin-3-one,
5-ethyl-6-(2-{4-[2-(pyrrolidin-1-yl)ethoxy]phenyl}-1,3-benzoxazol-6-yl)-2,3,4,5-tetrahydropyridazin-3-one,
6-[2-(4-{2-[bis(2-methylpropyl)amino]ethoxy}phenyl)-1,3-benzoxazol-6-yl]-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one,
5-ethyl-6-(2-{4-[3-(piperidin-1-yl)propoxy]phenyl}-1,3-benzoxazol-6-yl)-2,3,4,5-tetrahydropyridazin-3-one,
6-(2-{4-[2-(4-acetylpiperazin-1-yl)ethoxy]phenyl}-1,3-benzoxazol-6-yl)-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one,
1-(2-{4-[6-(4-ethyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl)-1,3-benzoxazol-2-yl]phenoxy}ethyl)piperidine-4-carbonitrile,
6-[2-(4-{2-[(1R,4S)-2-azabicyclo[2.2.1]heptan-2-yl]ethoxy}phenyl)-1,3-benzoxazol-6-yl]-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one,
tert-butyl 4-(2-{4-[6-(4-ethyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl)-1,3-benzoxazol-2-yl]phenoxy}ethyl)piperazine-1-carboxylate,
6-[2-(4-{2-[4-(butan-2-yl)piperazin-1-yl]ethoxy}phenyl)-1,3-benzoxazol-6-yl]-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one,
5-ethyl-6-(2-{4-[2-(2-oxopyrrolidin-1-yl)ethoxyl]phenyl}-1,3-benzoxazol-6-yl)-2,3,4,5-tetrahydropyridazin-3-one,
5-ethyl-6-[2-(4-{2-[4-(propan-2-yl)piperazin-1-yl]ethoxy}phenyl)-1,3-benzoxazol-6-yl]-2,3,4,5-tetrahydropyridazin-3-one,
(4R,5S)-6-[2-(4-{2-[bis(propan-2-yl)aminolethoxy]phenyl})-1,3-benzoxazol-6-yl]-5-methyl-4-propyl-2,3,4,5-tetrahydropyridazin-3-one,
(4S ,5S)-6-[2-(4-{2-[bis(propan-2-yl)amino]ethoxy}phenyl)-1,3-benzoxazol-6-yl]-5-methyl-4-propyl-2,3,4,5-tetrahydropyridazin-3-one,
(4S ,5S)-5-methyl-6-{2-[4-(propan-2-yloxy)phenyl]-1,3-benzoxazol-6-yl}-4-propyl2,3,4,5-tetrahydropyridazin-3-one,
(4S ,5S)-5-methyl-6-(2-{4-[3-(piperidin-1-yl)propoxy]phenyl}-1,3-benzoxazol-6-yl)-4-propyl-2,3,4,5-tetrahydropyridazin-3-one,
(4R,5R)-5-methyl-6-(2-{4-[2-(piperidin-1-yl)ethoxy]phenyl}-1,3-benzoxazol-6-yl)-4-propyl-2,3,4,5-tetrahydropyridazin-3-one,
(4R,5R)-6-[2-(4-methoxyphenyl)-1,3-benzoxazol-6-yl]-5-methyl-4-propyl-2,3,4,5-tetrahydropyridazin-3-one,
5-ethyl-6-{2-[4-(propan-2-yl)phenyl]-1,3-benzoxazol-6-yl}-2,3,4,5-tetrahydropyridazin-3-one,
6-{2-[4-(cyclopentyloxy)phenyl]-1,3-benzoxazol-6-yl}-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one,
5-ethyl-6-{2-[4-(morpholin-4-yl)phenyl]-1,3-benzoxazol-6-yl}-2,3,4,5-tetrahydropyridazin-3-one,
(4R,5R)-5-ethyl-4-methyl-6-{2-[4-(propan-2-yloxy)phenyl]-1,3-benzoxazol-6-yl}-2,3,4,5-tetrahydropyridazin-3-one,
(4R,5S)-5-ethyl-4-methyl-6-{2-[4-(propan-2-yloxy)phenyl]-1,3-benzoxazol-6-yl}-2,3,4,5-tetrahydropyridazin-3-one,
5-ethyl-6-{2-[4-(1-methoxyethyl)phenyl]-1,3-benzoxazol-6-yl}-2,3,4,5-tetrahydropyridazin-3-one,
5-ethyl-6-{2-[4-(oxolan-3-yloxy)phenyl]-1,3-benzoxazol-6-yl}-2,3,4,5-tetrahydropyridazin-3-one,
(4R,5R)-6-[2-(4-fluorophenyl)-1,3-benzoxazol-6-yl]-5-methyl-4-propyl-2,3,4,5-tetrahydropyridazin-3-one,
(4R,5R)-5-methyl-4-propyl-6-[2-(thiophen-2-yl)-1,3-benzoxazol-6-yl]-2,3,4,5-tetrahydropyridazin-3-one,
(4R,5R)-5-methyl-6-[2-(5-methylthiophen-2-yl)-1,3-benzoxazol-6-yl]-4-propyl-2,3,4,5-tetrahydropyridazin-3-one,
(4R,5R)-6-[2-(4-chlorophenyl)-1,3-benzoxazol-6-yl]-5-methyl-4-propyl-2,3,4,5-tetrahydropyridazin-3-one,
(4R,5R)-5-methyl-6-[2-(4-methylthiophen-2-yl)-1,3-benzoxazol-6-yl]-4-propyl-2,3,4,5-tetrahydropyridazin-3-one,
(4R,5R)-5-methyl-4-propyl-6-[2-(thiophen-3-yl)-1,3-benzoxazol-6-yl]-2,3,4,5-tetrahydropyridazin-3-one, -
(4R,5R)-6-[2-(furan-2-yl)-1,3-benzoxazol-6-yl]-5-methyl-4-propyl-2,3,4,5-tetrahydropyridazin-3-one,
(4R,5R)-6-[(2-(2,5-dimethylfuran-3-yl)-1,3-benzoxazol-6-yl]-5-methyl-4-propyl-2,3,4,5-tetrahydropyridazin-3-one,
(5R)-5-ethyl-6-[(2-(4-methoxyphenyl)-1,3-benzoxazol-6-yl]-2,3,4,5-tetrahydropyridazin-3-one,
(5R)-6-{2-[4-(dimethylamino)phenyl]-1,3-benzoxazol-6-yl}-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one,
(5S)-5-ethyl-6-{2-[4-(propan-2-yloxy)phenyl]-1,3-benzoxazol-6-yl}-2,3,4,5-tetrahydropyridazin-3-one,
(5R)-5-ethyl-6-{2-[4-(propan-2-yloxy)phenyl]-1,3-benzoxazol-6-yl}-2,3,4,5-tetrahydropyridazin-3-one,
(5S)-5-ethyl-6-{2-[4-(oxan-4-yloxy)phenyl]-1,3-benzoxazol-6-yl}-2,3,4,5-tetrahydropyridazin-3-one,
(5R)-5-ethyl-6-{2-[4-(oxan-4-yloxy)phenyl]-1,3-benzoxazol-6-yl}-2,3,4,5-tetrahydropyridazin-3-one,
(4R,5R)-5-methyl-6-(2-phenyl-1,3-benzoxazol-6-yl)-4-propyl-2,3,4,5-tetrahydropyridazin-3-one,
(4S ,5S)-4-butyl-5-methyl-6-(2-phenyl-1,3-benzoxazol-6-yl)-2,3,4,5-tetrahydropyridazin-3-one,
(4R,5S)-5-methyl-6-(2-phenyl-1,3-benzoxazol-6-yl)-4-(prop-2-en-1-yl)-2,3,4,5-tetrahydropyridazin-3-one,
(4R,5S)-6-{2-[4-(benzyloxy)phenyl]-1,3-benzoxazol-6-yl}-5-methyl-4-propyl-2,3,4,5-tetrahydropyridazin-3-one,
(4S ,5S)-6-{2-[4-(benzyloxy)phenyl]-1,3-benzoxazol-6-yl}-5-methyl-4-propyl-2,3,4,5-tetrahydropyridazin-3-one,
5-ethyl-6-(2-{3-[2-(pyrrolidin-1-yl)ethoxy]phenyl}-1,3-benzoxazol-6-yl)-2,3,4,5-tetrahydropyridazin-3-one,
(4S ,5 S)-6-[2-(4-hydroxyphenyl)-1,3-benzoxazol-6-yl]-5-methyl-4-propyl-2,3,4,5-tetrahydropyridazin-3-one,
6-(2-phenyl-1,3-benzoxazol-6-yl)-2,3-dihydropyridazin-3-one,
(4R,5R)-5-ethyl-4-methyl-6-{2-[4-(propan-2-yloxy)phenyl]-1,3-benzoxazol-6-yl}-2,3,4,5-tetrahydropyridazin-3-one,
5-ethyl-6-(2-{4-[2-(pyrrolidin-1-yl)propoxy]phenyl}-1,3-benzoxazol-6-yl)-2,3,4,5-tetrahydropyridazin-3-one,
5-ethyl-6-[2(4-{[1-(pyrrolidin-1-yl)propan-2-yl]oxy}phenyl)-1,3-benzoxazol-6-yl]-2,3,4,5-tetrahydropyridazin-3-one,
5-ethyl-6-{2-[4-(2-hydroxypropoxy)phenyl]-1,3-benzoxazol-6-yl}-2,3,4,5-tetrahydropyridazin-3-one,
5-ethyl-6-(2-{4-[(2-hydroxycyclohexyl)oxy]phenyl}-1,3-benzoxazol-6-yl)-2,3,4,5-tetrahydropyridazin-3-one,
5-ethyl-6-{2-[4-(prop-2-en-1-yloxy)phenyl]-1,3-benzoxazol-6-yl}-2,3,4,5-tetrahydropyridazin-3-one,
5-ethyl-6-{2-[4-(2-methoxyethoxy)phenyl]-1,3-benzoxazol-6-yl}-2,3,4,5-tetrahydropyridazin-3-one,
5-ethyl-6-[2-(4-{2-[ethyl(propan-2-yl)aminolethoxy]phenyl})-1,3-benzoxazol-6-yl]-2,3,4,5-tetrahydropyridazin-3-one,
6-(2-{3-[2-(2,6-dimethylmorpholin-4-yl)ethoxy]phenyl}-1,3-benzoxazol-6-yl)-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one,
5-ethyl-6-[2(3-{2-[methyl(propan-2-yl)amino]ethoxy}phenyl)-1,3-benzoxazol-6-yl]-2,3,4,5-tetrahydropyridazin-3-one,
5-ethyl-6-[2(3-{2-[ethyl(propan-2-yl)amino]ethoxy}phenyl)-1,3-benzoxazol-6-yl]-2,3,4,5-tetrahydropyridazin-3-one,
5-ethyl-6-[2(4-{2-[methyl(propan-2-yl)amino]ethoxy}phenyl)-1,3-benzoxazol-6-yl]-2,3,4,5-tetrahydropyridazin-3-one, 6-(2-{4-[2-(2,6-dimethylmorpholin-4-yl)ethoxy]phenyl}-1,3-benzoxazol-6-yl)-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one,
5-ethyl-6-[2-(4-{[1-(morpholin-4-yl)propan-2-yl]oxy}phenyl)-1,3-benzoxazol-6-yl]-2,3,4,5-tetrahydropyridazin-3-one,
6-(2-{4-[2-(diethylamino)ethoxy]phenyl }-1,3-benzoxazol-6-yl)-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one,
(4S ,5 S)-6-[2-(4-{2-[(R2R,6S)-2,6-dimethylmorpholin-4-yl]ethoxy }phenyl)-1,3-benzoxazol-6-yl]-5-methyl-4-propyl-2,3,4,5-tetrahydropyridazin-3-one,
6-[2-(4-{[(R1R,2R)-2(diethylamino)cyclohexyl]oxy}phenyl)-1,3-benzoxazol-6-yl]-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one,
5-ethyl-6-[2-(4-{[(1R,2R)-2-(piperidin-1-yl)cyclopentyl]oxy }phenyl)-1,3-benzoxazol-6-yl]-2,3,4,5-tetrahydropyridazin-3-one,
tert-butyl (2S)-2-{4-[6-(4-ethyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl)-1,3-benzoxazol-2-yl]phenoxymethyl}pyrrolidine-1-carboxylate,
tert-butyl (2R)-2-{4-[6-(4-ethyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl)-1,3-benzoxazol-2-yl]phenoxymethyl }pyrrolidine-1-carboxylate,
5-ethyl-6-[2-(4-{[2-methyl-1-(pyrrolidin-1-yl)propan-2-yl]oxy}phenyl)-1,3-benzoxazol-6-yl]-2,3,4,5-tetrahydropyridazin-3-one,
5-ethyl-6-[2-{4-[2-methyl-2-(pyrrolidin-1-yl)propoxy]phenyl}-1,3-benzoxazol-6-yl]-2,3,4,5-tetrahydropyridazin-3-one,
5-ethyl-6-[2-(3-{[1-(piperidin-1-yl)propan-2-yl]oxy }phenyl)-1,3-benzoxazol-6-yl]-2,3,4,5-tetrahydropyridazin-3-one,
5-ethyl-6-[2-(4-{[2-methyl-1-(morpholin-4-yl)propan-2-yl]oxy }phenyl)-1,3-benzoxazol-6-yl]-2,3,4,5-tetrahydropyridazin-3-one,
5-ethyl-6-(2-{4-[2-methyl-2-(morpholin-4-yl)propoxy]phenyl}-1,3-benzoxazol-6-yl)-2,3,4,5-tetrahydropyridazin-3-one,
5-ethyl-6-(2-{4-[(1-methylpiperidin-2-yl)methoxy]phenyl}-1,3-benzoxazol-6-yl)-2,3,4,5-tetrahydropyridazin-3-one,
5-ethyl-6-(2-{4-[(1-methylazepan-2-yl)oxy]phenyl }-1,3-benzoxazol-6-yl)-2,3,4,5-tetrahydropyridazin-3-one,
(5R)-5-ethyl-6-[2-(4-{[1-(piperidin-1-yl)propan-2-yl]oxy}phenyl)-1,3-benzoxazol-6-yl]-2,3,4,5-tetrahydropyridazin-3-one,
(5S)-5-ethyl-6-(2-{4-[2-(piperidin-1-yl)propoxy]phenyl}-1,3-benzoxazol-6-yl)-2,3,4,5-tetrahydropyridazin-3-one,
(5R)-5-ethyl-6-(2-{4-[2-(piperidin-1-yl)propoxy]phenyl}-1,3-benzoxazol-6-yl)-2,3,4,5-tetrahydropyridazin-3-one,
5-ethyl-6-(2-{4-[(2S)-pyrrolidin-2-ylmethoxy]phenyl}-1,3-benzoxazol-6-yl)-2,3,4,5-tetrahydropyridazin-3-one,
5-ethyl-6-(2-{4-[(2R)-pyrrolidin-2-ylmethoxy]phenyl}-1,3-benzoxazol-6-yl)-2,3,4,5-tetrahydropyridazin-3-one,
5-ethyl-6-[2-(4-{[(2S)-1-(propan-2-yl)pyrrolidin-2-yl]methoxy}phenyl)-1,3-benzoxazol-6-yl]-2,3,4,5-tetrahydropyridazin-3-one,
5-ethyl-6-[2-(4-{[(2R)-1-(propan-2-yl)pyrrolidin-2-yl]methoxy}phenyl)-1,3-benzoxazol-6-yl]-2,3,4,5-tetrahydropyridazin-3-one,
5-ethyl-6-[2-(4-{[(2S)-1-methylpyrrolidin-2-yl]methoxy}phenyl)-1,3-benzoxazol-6-yl]-2,3,4,5-tetrahydropyridazin-3-one,
5-ethyl-6-(2-{4-[2-(4-methylpiperidin-1-yl)ethoxy]phenyl}-1,3-benzoxazol-6-yl)-2,3,4,5-tetrahydropyridazin-3-one,
5-ethyl-6-(2-{4-[2-(4-propylpiperidin-1-yl)ethoxy]phenyl}-1,3-benzoxazol-6-yl)-2,3,4,5-tetrahydropyridazin-3-one,
6-{2-[4-(2-{3-azaspiro[5.5]undecan-3-yl}ethoxy)phenyl]-1,3-benzoxazol-6-yl}-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one,
6-[2(4-{2-[(2R,6S)-2,6-dimethylmorpholin-4-yl]ethoxy}phenyl)-1,3-benzoxazol-6-yl]-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one,
5-ethyl-6-(2-{4-[2-(thiomorpholin-4-yl)ethoxy]phenyl}-1,3-benzoxazol-6-yl)-2,3,4,5-tetrahydropyridazin-3-one,
5-ethyl-6-(2-{4-[2-(4-fluoropiperidin-1-yl)ethoxy]phenyl}-1,3-benzoxazol-6-yl)-2,3,4,5-tetrahydropyridazin-3-one,
5-ethyl-6-[2-(4-{2-[propan-2-yl(propyl)amino]ethoxy}phenyl)-1,3-benzoxazol-6-yl]-2,3,4,5-tetrahydropyridazin-3-one,
6-[2(4-{2-[(2R,5R)-2,5-dimethylpyrrolidin-1-yl]ethoxy}phenyl)-1,3-benzoxazol-6-yl]-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one,
5-ethyl-6-(2-{4-[(1-hydroxypropan-2-yl)oxy]phenyl}-1,3-benzoxazol-6-yl)-2,3,4,5-tetrahydropyridazin-3-one,
(4R,5R)-5-methyl-6-[2-(1-methyl-1H-pyrrol-2-yl)-1,3-benzoxazol-6-yl]-4-propyl-2,3,4,5-tetrahydropyridazin-3-one,
(4R,5R)-6-(2-cyclopropyl-1,3-benzoxazol-6-yl)-5-methyl-4-propyl-2,3,4,5-tetrahydropyridazin-3-one,
methyl 3-[6-(4-methyl-6-oxo-1,6-dihydropyridazin-3-yl)-1,3-benzoxazol-2-yl]benzoate,
4-[6-(4-methyl-6-oxo-1,6-dihydropyridazin-3-yl)-1,3-benzoxazol-2-yl]benzoic acid,
5-methyl-6-[2-(thiophen-2-yl)-1,3-benzoxazol-6-yl]-2,3-dihydropyridazin-3-one,
6-[2-(thiophen-2-yl)-1,3-benzoxazol-6-yl]-2,3-dihydropyridazin-3-one,
(5S)-6-[2-(4-{2-[bis(propan-2-yl)amino]ethoxy}phenyl)-1,3-benzoxazol-6-yl]-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one,
(5R)-6-[2-(4-{2-[bis(propan-2-yl)amino]ethoxy}phenyl)-1,3-benzoxazol-6-yl]-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one, and
(4R,5R)-5-methyl-6-{2-[4-(propan-2-yloxy)phenyl]-1,3-benzoxazol-6-yl}-4-propyl-2,3,4,5-tetrahydropyridazin-3-one,
or a tautomer, enantiomer, or a physiologically acceptable salt thereof.

### Claim 9 (depends on 1)

A medicament comprising a compound of formula I according to claim 1 or a physiologically acceptable salt thereof and an inert carrier or diluent.

### Claim 10 (depends on 1)

A method of modulating G protein-coupled receptor 119 activity in a patient in need thereof comprising administering to the patient a compound according to claim 1.

### Claim 11

The compound of formula I
wherein:
R1 is hydrogen, 1-4C-alkyl, 3-7C-cycloalkyl, 3-7C-cycloalkyl-1-4C-alkyl, 2-4C-alkenyl, 2-4C-alkynyl, 1-4C-alkoxy, 1-4C-alkoxy-1-4C-alkyl, wholly or partially fluorine-substituted 1-4C-alkyl, or wholly or partially fluorine-substituted 1-4C-alkoxy,
A is CR2R3, O, S, or NR2, wherein R2 is a group selected from hydrogen, 1-4C-alkyl, 3-7C-cycloalkyl, 3-7C-cycloalkyl-1-4C-alkyl, 2-4C-alkenyl, 2-4C-alkynyl, 1-4C-alkoxy, 1-4C-alkoxy-1-4C-alkyl, wholly or partially fluorine-substituted 1-4C-alkyl, or wholly or partially fluorine-substituted 1-4C-alkoxy, or R1 and R2 together represent a bond, or a 1-7C-alkanediyl group wherein one or two —CH2— groups each are optionally replaced by —O—, and R3 is hydrogen or 1-4C-alkyl, and
G is a bicyclic system G1or G2:
wherein:
R4 is a group optionally substituted by one to four R5 and/or R6 independently selected from 1-4C-alkyl, 3-7C-cycloalkyl, 3-7C-cycloalkyl-1-4C-alkyl, 2-4C-alkenyl, 2-4C-alkynyl, aryl, heteroaryl, aryl-1-4C-alkyl, heteroaryl-1-4C-alkyl, heterocyclyl, and heterocyclyl-1-4C-alkyl, wherein:
each R5 independently is hydrogen or a group optionally substituted by one to four R10 and/or R11 and/or R12 independently selected from 1-4C-alkyl, 3-7C-cycloalkyl, 3-7C-cycloalkyl-1-4C-alkyl, 2-4C-alkenyl, 2-4C-alkynyl, aryl, heteroaryl, heterocyclyl, aryl-1-4C-alkyl, heteroaryl-1-4C-alkyl, and heterocyclyl-1-4C-alkyl,
each R6 independently is hydrogen or a group selected from: halogen, trifluoromethyl, cyano, oxo, —OR7, —N(R7)R8, —SR7, —C(O)OR7, —C(O)N(R7)R8, —S(O)2N(R7)R8, —C(O)R9, —S(O)2R9, —S(O)R9, —N(R81)C(O)OR7, —N(R81)C(O)N(R7)R8, —N(R81)S(O)2N(R7)R8, —N(R81)C(O)R9, —N(R81)S(O)2R9, and —N(R81)S(O)R9,
wherein:
each R7 independently is hydrogen or a group optionally substituted by one to four R10 and/or R11 and/or R12 selected from 1-4C-alkyl, 3-7C cycloalkyl, 3-7C-cycloalkyl-1-4C-alkyl, 2-4C-alkenyl, 2-4C-alkynyl, aryl, heteroaryl, heterocyclyl, aryl-1-4C-alkyl, heteroaryl-1-4C-alkyl, and heterocyclyl-1-4C-alkyl,
each R8 independently is hydrogen or a group selected from 1-4C-alkyl and 3-7C-cycloalkyl, or R7 and R8 together represent a 1-9C-alkanediyl group wherein one or two —CH2— groups each are optionally replaced by —O, —NR81, —S, —SO, or —SO2—, wherein each R81 independently is hydrogen or 1-4C-alkyl,
each R9 independently is a group optionally substituted by one to four R10 and/or R11 and/or R12, each independently selected from 1-4C-alkyl, 3-7C-cycloalkyl, 3-7C-cycloalkyl-1-4C-alkyl, aryl, heteroaryl, heterocyclyl, aryl-1-4C-alkyl, heteroaryl-1-4C-alkyl, and heterocyclyl-1-4C-alkyl, wherein
each R10 independently is a group selected from hydrogen, 1-4C-alkyl, 3-7C-cycloalkyl, 3-7C-cycloalkyl-1-4C-alkyl, aryl, heteroaryl, heterocyclyl, aryl-1-4C-alkyl, heteroaryl-1-4C-alkyl, and heterocyclyl-1-4C-alkyl,
each R11 independently is hydrogen or a group selected from halogen, trifluoromethyl, cyano, oxo, —OR13, —N(R13)R14, and —SR13,
each R12 independently is hydrogen or a group selected from C(O)OR13, —C(O)N(R13)R14, —S(O)2N(R13)R14, —C(O)R15, —S(O)2R15—S(O)R15, —N(R141)C(O)OR13, —N(R141)C(O)N(R13)R14, —N(R141)S(O)2N(R13)R14, —N(R141)C(O)R15, —N(R141)S(O)2R15, and —N(R141)S(O)R15,
each R13 independently is a group selected from hydrogen, 1-4C-alkyl, 3-7C-cycloalkyl, 3-7C-cycloalkyl-1-4C-alkyl, aryl, heteroaryl, heterocyclyl, aryl-1-4C-alkyl, heteroaryl-1-4C-alkyl, and heterocyclyl-1-4C-alkyl,
each R14 independently is a group selected from hydrogen, 1-4C-alkyl and 3-7C-cycloalkyl, or R13 and R14 together represent a 1-9C-alkanediyl group wherein one or two —CH2— groups each are optionally replaced by —O, —NR141, —S, —SO, or —SO2—, wherein each R141 independently is hydrogen or 1-4C-alkyl,
each R15 independently is a group selected from 1-4C-alkyl, 3-7C-cycloalkyl, 3-7C-cycloalkyl-1-4C-alkyl, aryl, heteroaryl, heterocyclyl, aryl-1-4C-alkyl,heteroaryl-1-4C-alkyl, and heterocyclyl-1-4C-alkyl,
wherein:
aryl, on its own or as part of another group, is a carbocyclic aromatic monocyclic ring system containing 6 carbon atoms, which is optionally annelated to a second 5- or 6-membered carbocyclic aromatic, saturated or unsaturated ring system,
heteroaryl, on its own or as part of another group, is a 5- to 12-membered, aromatic, monocyclic or condensed-polycyclic ring system containing 1 to 4 heteroatoms independently selected from N, O, and S(O)r with r=0, 1, or 2, wherein at least one of the heteroatoms is part of the aromatic ring, and
heterocyclyl, on its own or as part of another group, is a 3- to 12-membered, saturated, unsaturated or aromatic, monocyclic or condensed, bridged or spiro-polycyclic ring system containing 1 to 4 heteroatoms independently selected from N, O, and S(O)r with r=0, 1, or 2, wherein none of the heteroatoms is part of the aromatic ring;
or a tautomer, enantiomer, or a salt thereof.